RAF1 and melanoma: Conversely, RAF inhibitors paradoxically enhance ERK activation and proliferation in BRAF-wildtype, RAS-mutant melanoma (and normal) cells through a mechanism that involves the interaction of these drugs with RAF dimers[7,30,31].